Nursing Elites

1. A healthcare professional is reviewing a new prescription for Ondansetron 4 mg PO PRN for nausea and vomiting for a client who has Hyperemesis Gravidarum. The healthcare professional should clarify which of the following parts of the prescription with the provider?

• A. Name
• B. Dosage
• C. Route
• D. Frequency

Correct answer: D

Rationale: The prescription provided includes the medication name, dosage, and route of administration. However, it lacks information about the frequency or timing of the medication administration. In this case, it is crucial to clarify the frequency with the provider to ensure the safe and effective use of the medication for the client with Hyperemesis Gravidarum.

2. A healthcare professional is teaching a client who has a new prescription for Clopidogrel. Which of the following laboratory values should the healthcare professional monitor to assess for potential adverse effects?

• A. White blood cell count
• B. Platelet count
• C. Hemoglobin
• D. Blood glucose

Correct answer: B

Rationale: Clopidogrel is an antiplatelet medication that works by preventing blood clots. Monitoring the patient's platelet count is essential because a decrease in platelet count can increase the risk of bleeding. By assessing the platelet count, the healthcare professional can detect any potential adverse effects related to the medication and take appropriate actions to prevent complications. White blood cell count, hemoglobin, and blood glucose levels are not directly affected by Clopidogrel, so they are not the primary values to monitor for potential adverse effects of this medication.

3. A healthcare professional is preparing to administer Butorphanol to a client who has a history of substance use disorder. The healthcare professional should identify which of the following information as true regarding Butorphanol?

• A. Butorphanol has a lower risk of abuse than morphine.
• B. Butorphanol causes a lower incidence of respiratory depression than morphine.
• C. Butorphanol can be reversed with an opioid antagonist.
• D. Butorphanol can cause abstinence syndrome in opioid-dependent clients.

Correct answer: D

Rationale: The correct answer is D. Butorphanol is an opioid agonist/antagonist that can precipitate withdrawal symptoms in opioid-dependent individuals. Symptoms of abstinence syndrome can include abdominal pain, fever, and anxiety. This occurs because butorphanol competes with and displaces opioid agonists from receptors, leading to withdrawal symptoms in opioid-dependent clients. Choices A, B, and C are incorrect. Butorphanol does not have a lower risk of abuse than morphine, it can cause respiratory depression similar to other opioids, and although it is an opioid antagonist, it does not get reversed by opioid antagonists.

4. A healthcare provider is caring for a client who has a new prescription for Clonidine. Which of the following adverse effects should the healthcare provider monitor?

• A. Drowsiness
• B. Dry mouth
• C. Weight gain
• D. Insomnia

Correct answer: B

Rationale: The correct answer is B: Dry mouth. Dry mouth is a common adverse effect of Clonidine. Clonidine can cause a reduction in salivary flow, leading to dry mouth. This symptom can be managed by increasing fluid intake or using sugar-free gum or candy to stimulate saliva production. Choices A, C, and D are incorrect. While drowsiness and insomnia are potential side effects of Clonidine, dry mouth is more commonly reported. Weight gain is not typically associated with Clonidine use.

5. A client with heart failure is receiving instructions about laxative use. The client should be advised to avoid which of the following laxatives?

• A. Sodium phosphate
• B. Psyllium
• C. Bisacodyl
• D. Polyethylene glycol

Correct answer: A

Rationale: Clients with heart failure often have sodium restrictions. Sodium phosphate can lead to fluid retention due to sodium absorption, which is harmful for individuals with heart failure. Therefore, it should be avoided in this population to prevent exacerbating fluid overload. Psyllium, Bisacodyl, and Polyethylene glycol are safer options for individuals with heart failure as they do not pose the risk of exacerbating fluid overload through sodium retention.

Similar Questions